| abstract |
REFERS TO PHARMACEUTICAL COMPOUNDS OF FORMULA I WHERE R1 IS H, C1-C8 ALKYL, C3-C6 CYCLOALKYL, C0-C4 ARYLALKYL, AMONG OTHERS; R2 IS C1-C8 ALKYL, C3-C6 CYCLOALKYL, C0-C4 ARYLALKYL, AMONG OTHERS; E IS C0-C4 ARYLALKYL, C1-C4 THIOALKYL, THIOARYL, AMONG OTHERS; R5 AND R6 ARE EACH H, C1-C8 ALKYL, C0-C4 ARYLALKYL, C0-C4 HETEROARYALKYL, AMONG OTHERS. YOUR PREFERRED COMPOUNDS ARE: (2S, 1'R) -2-ETOXY-3- (4- {1 '- [2- (4-PHENOXY-PHENYL) -ETHYLCARBAMOYL] -ETOXY} -PHENYL) -PROPIONIC ACID AND (2S, 1'R) -2-ETHOXY-3- (4- {1 '- [2- (4-ETHYL-PHENYL) -ETHYLCARBAMOYL] -ETOXY} -PHENYL) -PROPIONIC; AMONG OTHERS. SUCH COMPOUNDS ARE USEFUL PPAR AGONISTS IN THE TREATMENT OF DIABETES AND / OR RELATED CLINICAL PATHOLOGICAL STATES |